Abeona Therapeutics Inc vs Herbalife Nutrition Ltd — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Herbalife Nutrition Ltd trades at $11.76 (market cap $1.23B). The key difference: Herbalife Nutrition Ltd is far larger — about 2.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Herbalife Nutrition Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | HLF | |
|---|---|---|
Market Cap | $421.19M | $1.23B |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $19.96 |
52-Week Low | $4.17 | $7.75 |
Enterprise Value | $276.10M | $3.06B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
HLF trades at $11.71, up 1.65% on the day, with a bearish technical signal from moving averages. The company shows mixed earnings, missing Q2 2026 EPS estimates but achieving four consecutive quarters of sales growth. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24, though negative shareholder equity and high debt levels present financial risks. Recent news includes a planned CFO transition and inclusion in TIME's America's Best Companies 2026 list.
The outlook for HLF balances low valuation against operational and financial challenges. Investment opportunity lies in potential margin improvement and debt reduction, but risks include earnings volatility, high leverage, and competitive pressures in the nutrition space. Analyst sentiment is cautiously optimistic with a majority buy rating.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →